Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to patients with advanced breast cancer, especially to those with hormone receptor (HR)‐positive, human epidermal growth factor receptor (HER) 2‐negative advanced breast cancer. This evidence concerns the gene PIK3CG and breast carcinoma.